// App-Quantinova.ai

P08.02 : Lorlatinib in First Line Treatment of Patients With ALK-Positive NSCLC: A Network Meta-Analysis

Researchers

Presenter

  • J. Gregory

Principal Investigators

  • T. Williams

  • M. Cooper

  • S. Ou

Medical Centers

  • Pfizer Inc, New York, NY

  • Bresmed Health Solutions, Sheffield/GB

  • University of California, Irvine, Orange, CA, USA

  • Pfizer Inc, Milan/IT

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • brigatinib

  • Lorlatinib

  • Crizotinib

  • Alectinib

  • Ceritinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03052608

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved